52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
J&J Announces Agreement With U.S. Government For 100 Mln Doses Of Investigational Covid-19 Vaccine
Janssen Announces Health Canada Approval Of Darzalex Subcutaneous Formulation For Multiple Myeloma
Janssen Announces U.S. FDA Approval of Spravato CIII Nasal Spray
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Biotechnology & Drugs
1 Johnson And Johnson Plz
NEW BRUNSWICK, NJ
Chairman of the Board, Chief Executive Officer
Paulus A. Stoffels
Vice Chairman- Executive Committee, Chief Scientific Officer
Joaquin Boix Duato
Vice Chairman - Executive Committee
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The United States government will pay Johnson & Johnson <JNJ.N> over $1 billion for 100 million doses of its potential coronavirus vaccine, as it stocks up on vaccine and drugs in an attempt to tame the pandemic.
Johnson & Johnson <JNJ.N> on Thursday kicked off U.S. human safety trials for its COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing vaccine candidate offered strong protection in a single dose.
(Adds Osaka University, Kentucky Bioprocessing, Vaxine, Medigen; Updates CureVac, J&J, GSK) July 29 (Reuters) - More than 150 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, with 25 in human clinical trials, according to the World...
Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of its potential COVID-19 vaccine as it prepares to kick off human trials, the company's Chief Financial Officer Joseph Wolk told Reuters in...
Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of its potential COVID-19 vaccine in advance of it producing any of the medicines, the company's Chief Financial Officer Joseph Wolk told Reuters...
Johnson & Johnson said on Thursday it is aiming to begin in September a late-stage study of its experimental vaccine for the novel coronavirus, as researchers work at break-neck speed to develop a shot to combat the fast-spreading pathogen.
Johnson & Johnson said on Thursday it was in talks to begin late-stage studies of its experimental coronavirus vaccine in September.
Johnson & Johnson raised its full-year profit forecast and beat analysts' estimates for quarterly earnings on Thursday as strength in its pharmaceuticals unit cushioned a steep fall in sales of its medical devices due to the COVID-19 pandemic.
Johnson & Johnson reported a 35.3% fall in second-quarter profit on Thursday as demand for its medical devices was hammered by hospitals putting off non-urgent procedures such as knee and hip replacement due to the COVID-19 pandemic.
Johnson & Johnson's <JNJ.N> Cilag Holding will offer up to approximately 11.8 million existing ordinary shares in Idorsia Ltd <IDIA.S> in an accelerated bookbuilding to commence on Wednesday, the transaction's bookrunner said.
More than 170 nonprofit groups on Wednesday called for Johnson & Johnson <JNJ.N> to stop selling its talc-based Johnson’s Baby Powder world-wide, citing concerns that it contains cancer-causing asbestos, according to a statement from advocacy group Black Women for Wellness.
Johnson & Johnson <JNJ.N> said on Monday it was slashing the price of its version of tuberculosis drug bedaquiline to $340 from $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.
Johnson & Johnson said on Monday it was slashing the price of its version of the tuberculosis drug bedaquiline to $340 from its original price of $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.
* J&J - EFFECTIVE IMMEDIATELY, CO WILL MAKE BEDAQUILINE AVAILABLE TO STOP TB PARTNERSHIP’S GLOBAL DRUG FACILITY AT $340 PER SIX-MONTH TREATMENT COURSE
Emergent BioSolutions Inc <EBS.N> said on Monday it signed a five-year contract to make the drug substance used in Johnson & Johnson's <JNJ.N> COVID-19 vaccine candidate, adding to a series of deals likely to put it at the heart of future global vaccine production.
* EMERGENT BIOSOLUTIONS SIGNS FIVE-YEAR AGREEMENT FOR LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S LEAD COVID-19 VACCINE CANDIDATE
Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.
Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus as it was not found to be effective against the auto-immune disease.
Johnson & Johnson's Janssen unit said on Friday it would discontinue a late-stage study testing its psoriatic arthritis drug Stelara as a treatment for lupus due to lack of efficacy.
A Missouri appeals court on Tuesday rejected Johnson & Johnson's bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on its baby powder and other talc products, but reduced damages by more than half, to $2.12 billion.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.